03:35 AM EDT, 08/08/2022 (MT Newswires) -- Austar Lifesciences (HKG:6118) forecast at least 43 million yuan ($6.4 million) in profit attributable to owners in the first half.
The technology-based pharmaceutical engineering solution provider logged 218 million yuan in profit in the year prior.
The expected profit fall is mainly attributed to the one-off net gain before income tax of 199 million yuan from the company's disposal of its 60% equity interest in a joint venture in the year-ago period.
Austar's interim results announcement is expected to be released in late August.
Price (HKD): $2.46, Change: $+0.01, Percent Change: +0.41%